Key Drivers
- Strong liquidity
- Persistent losses
- Negative FCF
AIAI Summary
Arvinas has shifted from a one‑asset binary bet to a platform-driven, multi-catalyst biotech with ~H2 2028 cash runway that materially lowers near-term financing risk, but the stock's upside now depends on serial Phase‑1 de‑risking (and the vepdegestrant regulatory outcome) — actionable watchpoints: upcoming Phase‑1 readouts, adherence to sub‑$75M quarterly spend, and any changes to dilution or partnership cadence.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Persistent losses
- •Negative FCF
ARVN has strong liquidity and low leverage but persistent operating losses and deeply negative free cash flow that threaten sustainability without financing or revenue improvement.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Elevated volatility
- •Support test imminent
ARVN is in a short-term downtrend—below the last-month SMA (~$12.72) after an ~8.8% decline, facing resistance near $13.83 and critical support at ~$10.89 that must hold for recovery.
Large last-month range (~$13.83 to ~$10.89) with an ~8.8% drop indicating elevated short-term volatility
Sentiment & News
Key News Insights:
- •Wider Q4 loss
- •Positive ARV‑102
- •Cash runway H2‑2028
Arvinas missed Q4 expectations with a wider loss and shifted toward early‑stage programs with cash into H2 2028, but delivered a positive Phase 1 ARV‑102 CNS biomarker readout and set multiple 2026 clinical catalysts.
Financial weakness could weigh on the stock near term, but the ARV‑102 data and upcoming 2026 catalysts provide R&D-driven upside for investors
Similar Companies in Healthcare
Other companies in the same sector with AI ratings